Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials

DOI10.1515/IJB-2020-0147MaRDI QIDQ6637076

Ami Takahashi, Taiji Suzuki

Publication date: 13 November 2024

Published in: The International Journal of Biostatistics (Search for Journal in Brave)

zbMATH Keywords

maximum tolerated dosecombination therapynonparametric methodBayesian optimizationphase I clinical trials

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Title not available (Why is that?)
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Efficient global optimization of expensive black-box functions
• Continual Reassessment Method for Partial Ordering
• Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
• Convergence rates of efficient global optimization algorithms
• Two‐Dimensional Dose Finding in Discrete Dose Space
• Bayesian optimal interval designs for phase I clinical trials

This page was built for publication: Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6637076)